论文部分内容阅读
为了探讨无严重应激和并发症的NIDDM患者改用或加用胰岛素的指针，我们分析了116例MIDDM住院患者的临床资料，发现空腹血糖（FBG）大于16．7mmol／L或糖耐量2小时血糖（2BG）大于27．8mmol／L的病人，一般需用或加用胰岛素治疗；FBG＜11．1mmol／L或2BG＜16．7mmol／L的病人，一般不需用胰岛素；两者之间者，可结合临床作出判断。胰岛素体内分泌量作为指导用药指标的准确性较差。因而FBG与2BG是一种较好的指导用药的指标。
To investigate the use of or addition of insulin in NIDDM patients without severe stress and complications, we analyzed the clinical data of 116 patients with MIDDM and found that fasting blood glucose (FBG) was greater than 16.7 mmol / L or glucose tolerance for 2 hours Blood glucose (2BG) greater than 27.8mmol / L of patients, generally require or add insulin therapy; FBG <11.1mmol / L or 2BG <16.7mmol / L of patients, generally do not need insulin; between the two Can be combined with clinical judgment. Insulin secretion in vivo as a guide to the accuracy of the index is poor. Thus FBG and 2BG is a good indicator of medication.